比较伊朗肥胖或超重人群与非肥胖人群的抗乙型肝炎抗体水平。
Comparing Anti-hepatitis B Antibody Level in Iranian Obese or Overweight with Non-obese Cases.
作者信息
Kabir Ali, Pazouki Abdolreza, Jafari Motahareh, Mokhber Somayye, Vaziri Mohammad, Alavian Seyed Moayed
机构信息
Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Tehran, Iran.
Middle East Liver Disease Center, Tehran, Iran.
出版信息
Iran Biomed J. 2017 May;21(3):197-202. doi: 10.18869/acadpub.ibj.21.3.197. Epub 2017 Feb 14.
BACKGROUND
There is a controversy about the relation between anti-hepatitis B (anti-HBs) antibody level and obesity. We designed this study to compare the vaccine efficacy in obese/overweight and non-obese cases.
METHODS
In this cross-sectional study, 242 obese/overweight and 85 non-obese individuals were participated. Cases were selected from a referral clinic for obesity and a referral hepatology clinic, both in Tehran, Iran.
RESULTS
Obese cases had lower percentage of liver diseases (66.9% vs. 100%, P<0.001) but higher hepatitis B vaccination history (74.9% vs. 51.2%, P<0.001). Median±inter-quartile range of anti-HBs titer in obese cases was significantly lower than controls (48.5±194.5 vs. 100±557.6, P=0.012).
CONCLUSION
The level of anti-HBs surface antigen antibody's titer in obese cases without liver disease is lower than control group. Therefore, a suitable strategy is needed to overcome this problem, which can be the use of longer needles for vaccination.
背景
关于抗乙型肝炎（抗-HBs）抗体水平与肥胖之间的关系存在争议。我们设计了本研究，以比较肥胖/超重和非肥胖病例中的疫苗效力。
方法
在这项横断面研究中，纳入了242例肥胖/超重个体和85例非肥胖个体。病例选自伊朗德黑兰的一家肥胖转诊诊所和一家肝病转诊诊所。
结果
肥胖病例中肝脏疾病的比例较低（66.9%对100%，P<0.001），但乙肝疫苗接种史较高（74.9%对51.2%，P<0.001）。肥胖病例中抗-HBs滴度的中位数±四分位间距显著低于对照组（48.5±194.5对100±557.6，P=0.012）。
结论
无肝脏疾病的肥胖病例中抗-HBs表面抗原抗体的滴度水平低于对照组。因此，需要一种合适的策略来克服这一问题，这可能是使用更长的针头进行疫苗接种。
Zotero 插件